Solifenacin succinate 1mg/mL; oral susp; orange-flavor. Take once daily, followed by liquid (eg, water or milk). Avoid taking at the same time with food or other drinks. Missed dose: take as soon as ...

The Scottish Medicines Consortium, Scotland’s equivalent to the National Institute for Health and Clinical Excellence in England and Wales, has decided to back the use of Astellas Pharma’s Vesicare ...

The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.

Vesicare is the first overactive bladder treatment at an approved dose to show a statistically significant increase in warning time before urination Christchurch, New Zealand – December 1, 2006 – ...

Teva Pharmaceutical announced the launch of its generic version of Vesicare. The tablets, which are available in 5 mg and 10 mg in the United States, are a solifenacin succinate indicated for the ...

WALTHAM, Mass., April 3, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on ...

The US Food and Drug Administration (FDA) granted approval to VESIcare LS (solifenacin succinate) oral suspension, a liquid taken by mouth, for the treatment of neurogenic detrusor overactivity (NDO), ...

The US Food and Drug Administration (FDA) has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate (Vesicare, Astellas Pharma) for the treatment of overactive ...

Camber is introducing solifenacin succinate tablets, which are the generic of Vesicare. The medication is used to treat symptoms of overactive bladder, such as frequent or urgent urination and ...

Hi Doc Thanks for the reply to my earlier question about taking Vesicare & Trepiline for my bladder problems. I would just like to please know could I not change the dosage of Trepiline to, say, 25mg ...

Nov. 23, 2004 — The U.S. Food and Drug Administration (FDA) has approved solifenacin succinate for the treatment of overactive bladder, erlotinib as second-line therapy for locally advanced or ...

Astellas tapped independent agency Roska Healthcare as consumer agency-of-record for Astellas’ new overactive bladder pill, Myrbetriq (mirabegron). The agency announced the win in August, just over a ...